Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
We monitor for this closely during the initial phases of treatment
Review Medical Risks Kidney or liver disease, fluid restrictions, heart failure, pregnancy, allergy history, prior infusion reactions, vein access, and current cancer treatment can change the risk-benefit assessment
My stomach looked deflated
Chemoresistance towards EGFR inhibition by small molecule tyrosine kinase inhibitors such as gefitinib or erlotinib are common features in clinical trials
US$ 24.10
US$ 27.28
US$ 23.43
US$ 21.37
US$ 22.90
